Suven-Cohance Merger Approved by NCLT
In brief · AI summary The National Company Law Tribunal approved the merger of Suven Pharmaceuticals with Cohance Lifesciences on March 27, 2025, and the deal will take effect once all regulatory conditions are met. Approval from the Department of Pharmaceuticals is still required, with completion expected by Q1FY26. The combined company aims to reach $1 billion in revenue in five years and will focus on antibody drug conjugates, oligonucleotides, and small molecules.
Amalgamation to Create a Diversified CDMO Leader
Suven Pharmaceuticals has received NCLT approval to merge with Cohance Lifesciences. The tribunal sanctioned the deal on March 27, 2025.
What’s Next?
The merger will take effect after meeting all regulatory conditions. Approval from the Department of Pharmaceuticals is still required. The process is expected to be completed by Q1FY26.
Growth and Expansion
The combined entity will focus on:
- Antibody Drug Conjugates (ADCs)
- Oligonucleotides
- Small Molecules
This merger will boost Suven’s global capabilities and strengthen its CDMO and API+ business.
Future Prospects
Suven aims to reach $1 billion in revenue in five years. The merger will enhance scale, innovation, and operational efficiency. The pharma giant is now set to deliver high-impact solutions to global clients.